SCHEMBL3384555

SCHEMBL3384555

COCCn1cc(C)s/c1=N\C(=O)c1cc(Cl)ccc1OC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 5/20 0.48
LMNA P02545 1/20 0.43
PIM1 P11309 1/20 0.42
CLK2 P49760 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
HPGD P15428 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 5/20 0.41
TP53 P04637 1/20 0.41
KCNMA1 Q12791 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
ATM Q13315 1/20 0.40
THRB P10828 1/20 0.40
TSHR P16473 1/20 0.40
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3384559 1.00 CNR2 (0.48) CNR2LMNAPIM1CLK2CLK4
SCHEMBL3384757 0.94 CNR2 (0.45) CNR2LMNAPIM1CLK2CLK4
SCHEMBL3384760 0.94 CNR2 (0.45) CNR2LMNAPIM1CLK2CLK4
SCHEMBL3384647 0.90 CNR2 (0.49) CNR2PIM1CLK2CLK4HPGD
SCHEMBL3384652 0.90 CNR2 (0.49) CNR2PIM1CLK2CLK4HPGD
SCHEMBL3386343 0.89 PIM1 (0.52) CNR2LMNAPIM1CLK2CLK4
SCHEMBL3386345 0.89 PIM1 (0.52) CNR2LMNAPIM1CLK2CLK4
SCHEMBL3386066 0.88 CNR2 (0.44) CNR2PIM1CLK2CLK4HPGD
SCHEMBL3386060 0.88 CNR2 (0.44) CNR2PIM1CLK2CLK4HPGD
SCHEMBL344667 0.88 CNR2 (0.53) CNR2LMNAHPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841334-B2 Compounds as cannabinoid receptor ligands and uses thereof ABBVIE INC. (US) 2014-09-23 US disclosed
EP-2222165-B1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC (US) 2013-07-31 EP disclosed
EP-2222165-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-09-01 EP disclosed
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-04-15 US disclosed
WO-2009067613-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093814-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 CNR2 2/4885LMNA 1606/4885PIM1 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.